May 2013 Volume 9, Issue 5
Volume 9, Issue 5 | May 2013
May 2013
In this Issue
Editor's Focus
The many colors of sequestration
In researching our cover story on the sequestration -- or, put in very stark, black-and-white terms, $85 billion in across-the-board cuts to federal government spending -- and how it is expected to affect biomedical research in every state, I was treated to a slew of colorful comparisons by researchers, trade groups and government leaders, as they grapple to explain the hit they will take when the NIH is forced to cut its budget by 5.1 percent, or $1.6 billion, this fiscal year.Feature
ISSCR 2013 Show Preview: From stem to stern
ISSCR meeting keeps up with fast pace of stem cell research by offering increased technology element, expanded poster coverage and moreISSCR 2013 Show Preview (continued)
Additional stories relevant to ISSCR 11th Annual Meeting in Boston, plus more photosOmics & Systems Biology
Soaking up some UVP rays
Analytik Jena acquires imaging systems developer UVP and subsidiaryFrom lab to clinic in the Sunshine State
First five projects named to pilot Florida Translational Research ProgramA sweet deal
Agilent Technologies and Chungnam National University collaborate on glycomics research education centerPartners in search of a prognosis
OGT granted prostate cancer biomarker license by the ICRGlobal News
Developing answers for developing nations
Five Japanese pharmas form public-private partnership with their government to help developing countries fight infectious diseasesA partnership with some pep(tides)
Ipsen, PeptiDream team up for therapeutic peptides to treat serious conditionsGetting personal about profiling
PerkinElmer will team up with China’s National Center for Drug Screening to advance personalized medicine and drug profilingCoordinated TAKTIC
Six-way partnership attempts synergy in inhibiting protein kinases to develop novel drugsTwo ways to look at it
Roche looks to combine Isis’ antisense oligonucleotide program with its own ‘brain shuttle’ program to take down Huntington’s diseaseTools & Technology
Life for Thermo
Thermo Fisher Scientific acquires Life Technologies for $13.6 billionNext-gen data dynamic duo
IBM and CLC bio pair up to deliver combined turnkey genomics sequencing analytics solutionTAPs for Thermo Fisher
Company and U.K.’s U of Birmingham become Technology Alliance Partners to advance LC-MS techniques in life-science researchGaining ground with genomics
NextBio, Genophen partner to advance genomics in personalized medicineCore Informatics and OpenEye Scientific Software forge partnership
Core Informatics and OpenEye Scientific Software announce partnership and their integration of OpenEye cheminformatics software into Core Informatics’ web-based Laboratory Information Management System and Electronic Lab NotebookRockland Immunochemicals acquires antibody line from 21st Century Biochemicals
Biotechnology company Rockland Immunochemicals Inc. has acquired the Epi-Plus antibody product line from 21st Century Biochemicals Inc.Government Watch
‘2013: A bad year to have a good idea’
Sequestration takes $1.6 billion bite out of NIH-funded researchPatent Docs: Supreme Court’s consideration of IP rights exhaustion impacts pharma, biotech industries
The U.S. Supreme Court has been considering exhaustion of intellectual property rights this term, and in one case decided and one pending, these considerations could impact the availability of meaningful patent protection for drugs, vaccines and other biological productsHalf a loaf, maybe
Supreme Court hears arguments challenging patents on breast, ovarian cancer genesStates beg to differ on biosimilar concerns
Maryland becomes fourth U.S. state to reject laws restricting biosimilar substitutionResearch & Development
Straight A's with ADCs
Astellas, Ambrx to collaborate on ADCs for oncology targetsNanomedicine: The next (not-so-) big thing
BIND Therapeutics announces collaboration with Pfizer to develop nanoparticle-based therapeuticsMedImmune makes a move
MedImmune acquires AlphaCore, gains novel compound based on LCAT enzymeA pair of model-building aficionados
Crown Bioscience and Horizon Discovery forge two-year deal to offer combined solutions for in-vivo oncology model developmentNew hope for a cruel disease
Israel’s BrainStorm partners with New York’s Dana-Farber in Phase II ALS clinical trial to treat Lou Gehrig’s diseaseDiagnostics
All about antibodies
OriGene acquires SDIX’s life-science business assetsA firm foundation for Agios
Agios Pharmaceuticals partners with Foundation Medicine for IDH1 and IDH2 cancer metabolism programsThe power of prediction
CvergenX partners with NCI to predict best candidates for radiation therapyTo cancer and beyond
CollabRx Partners with Sengenics for molecular diagnostics, with cancer as initial focus areaCommentary
Facing the patent cliff head-on
With the loss of patent protection on so many blockbuster drugs, Big Pharma’s financial outlook is entering a new phase of opportunity.Out of Order: Attention to detail
Molecular biological advances have changed our world for the good, and I am the first to jump up and applaud them. But it is equally important that we don’t let the volume of that applause drown out the voices that offer alternative solutions.
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
Automating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
A closer look at the tumor microenvironment
New technologies are allowing researchers to delve deeper into the complex tumor landscape.
